相似文献
1
Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
Food Drug Law J. 2007;62(4):653-94.
2
Medicine goes Madison Avenue: an evaluation of the effect of direct-to-consumer pharmaceutical advertising on the learned intermediary doctrine.
Spec Law Dig Health Care Law. 1998 Dec(236):9-29.
3
Highlights and a hidden hazard--the FDA's new labeling regulations.
N Engl J Med. 2006 Jun 8;354(23):2409-11. doi: 10.1056/NEJMp068119.
4
The case for preemption of prescription drug failure-to-warn claims.
Food Drug Law J. 2007;62(2):399-422.
5
The learned intermediary doctrine: past, present and future.
Leg Med. 1994:269-80.
6
Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Food Drug Law J. 2006;61(4):585-622.
7
FDA's regulation of prescription drug labeling: a role for implied preemption.
Food Drug Law J. 2007;62(1):227-47.
8
The federal preemption debate in pharmaceutical labeling product liability actions.
Tort Trial Insur Pract Law J. 2007 Fall;43(1):35-70.
9
To inform or persuade? Direct-to-consumer advertising of prescription drugs.
N Engl J Med. 2005 Jan 27;352(4):325-8. doi: 10.1056/NEJMp048357.
10
Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
JAMA. 2009 May 20;301(19):2036-7. doi: 10.1001/jama.2009.680.
引用本文的文献
1
Pharmaceutical marketing: the example of drug samples.
J Pharm Policy Pract. 2022 Nov 7;15(1):78. doi: 10.1186/s40545-022-00479-z.
2
No more free drug samples?
PLoS Med. 2009 May 5;6(5):e1000074. doi: 10.1371/journal.pmed.1000074. Epub 2009 May 12.
Zotero 插件